Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.

The simultaneous inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Compound 23 has been found to be a potent dual kinase-bromodomain inhibitor (BRD4-BD1 IC50 = 28 nM, PLK1 IC50 = 40 nM). Compound 6 was found to be the most selective PLK1 inhibitor over BRD4 in our series (BRD4-BD1 IC50 = 2579 nM, PLK1 IC50 = 9.9 nM). Molecular docking studies with 23 and BRD4-BD1/PLK1 as well as with 6 corroborate the biochemical assay results.

[1]  I. Waizenegger,et al.  Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo. , 2018, Cancer letters.

[2]  James E. Bradner,et al.  A chemical probe toolbox for dissecting the cancer epigenome , 2017, Nature Reviews Cancer.

[3]  D. Durden,et al.  Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis , 2017, Proceedings of the National Academy of Sciences.

[4]  Christopher J. Ott,et al.  Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET‐BRET , 2016, ChemMedChem.

[5]  J. Sicklick,et al.  Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma , 2016, Molecular Cancer Therapeutics.

[6]  N. Ahmad,et al.  Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics , 2016, Molecular Cancer Therapeutics.

[7]  James E. Bradner,et al.  Response and resistance to BET bromodomain inhibitors in triple negative breast cancer , 2015, Nature.

[8]  Sarah Seton-Rogers,et al.  Epigenetics: Place your BETs , 2015, Nature Reviews Cancer.

[9]  Panagis Filippakopoulos,et al.  Beating the odds: BETs in disease. , 2015, Trends in biochemical sciences.

[10]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[11]  J. Qi,et al.  Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). , 2015, Pharmaceutical patent analyst.

[12]  William J. Allen,et al.  DOCK 6: Impact of new features and current docking performance , 2015, J. Comput. Chem..

[13]  J. Strovel,et al.  BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. , 2015, ACS medicinal chemistry letters.

[14]  Wei Zhang,et al.  Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors , 2014, Journal of medicinal chemistry.

[15]  Roberto Sanchez,et al.  The bromodomain: from epigenome reader to druggable target. , 2014, Biochimica et biophysica acta.

[16]  S. Knapp,et al.  Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.

[17]  L. Wodicka,et al.  Dual kinase-bromodomain inhibitors for rationally designed polypharmacology , 2014, Nature chemical biology.

[18]  H. Weinmann,et al.  Bromodomains and Their Pharmacological Inhibitors , 2014, ChemMedChem.

[19]  S. Olesen,et al.  Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors , 2014, ACS chemical biology.

[20]  P. P. Sharp,et al.  BET bromodomain inhibitors: a patent review , 2014, Expert opinion on therapeutic patents.

[21]  R. Siliciano,et al.  BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism , 2013, Cell cycle.

[22]  S. Knapp,et al.  Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit , 2012, Journal of medicinal chemistry.

[23]  S. Knapp,et al.  Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. , 2012, Journal of medicinal chemistry.

[24]  Zijuan Zhang,et al.  Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy. , 2012, Molecular bioSystems.

[25]  J. Greenbaum,et al.  Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors , 2012, Proceedings of the National Academy of Sciences.

[26]  Stefan Knapp,et al.  The bromodomain interaction module , 2012, FEBS letters.

[27]  Nathan Brown,et al.  Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites , 2012, Journal of medicinal chemistry.

[28]  E. Nicodème,et al.  From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. , 2012, Bioorganic & medicinal chemistry letters.

[29]  R. Prinjha,et al.  Place your BETs: the therapeutic potential of bromodomains. , 2012, Trends in pharmacological sciences.

[30]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[31]  C. Rice,et al.  Suppression of inflammation by a synthetic histone mimic , 2010, Nature.

[32]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[33]  Qiang Zhou,et al.  Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.

[34]  J. Brady,et al.  The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. , 2005, Molecular cell.

[35]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[36]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[37]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[38]  Christopher I. Bayly,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validation , 2002, J. Comput. Chem..

[39]  J. Ponder,et al.  An efficient newton‐like method for molecular mechanics energy minimization of large molecules , 1987 .

[40]  Norman L. Allinger,et al.  Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms , 1977 .

[41]  C. Chung.  Small molecule bromodomain inhibitors: extending the druggable genome. , 2012, Progress in medicinal chemistry.